| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Antheia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.29M | Series C-1 | 6/3/2025 | $73.99M | $160.77M | $0.84 | Global Health Investment Corporation, ATHOS KG, Federov, Viking Global, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel, Civilization Ventures, America's Frontier Fund | ||||
 | Altos Labs | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $105.00K | $260.00K | 1 | 1 | $18.00 | +33.33% | +5.88% | $11.13B | Series C | 2/14/2024 | $1.5B | $6.33B | $25.02 | Undisclosed Investors | ||||
 | Life Biosciences | Healthcare Biotech & Pharma | Medium | $xx.xx | $xx.xx | $xx.xx | xx% | $819.75K | -- | 6 | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Precision Neuroscience | Healthcare Biotech & Pharma | Medium | $xx.xx | $xx.xx | $xx.xx | xx% | $100.00K | $2.39M | 1 | 7 | $8.50 | +49.12% | +49.12% | $429.09M | Series D | 9/24/2026 | $250M | $1.03B | $7.20 | Pershing Square, Ackman Oxman Institute, Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, JSL Health Capital | ||||
 | ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $352.5M | Series C | 8/9/2023 | $200M | $848.26M | $9.75 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | ||||
 | Endeavor BioMedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.58M | Series C | 4/24/2024 | $132.58M | $676.04M | $6.52 | AyurMaya, Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, Abrdn Inc, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, T. Rowe Price Associates | ||||
 | Insitro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.26B | Series C | 3/15/2021 | $400M | $2.57B | $18.29 | CPP Investments, Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, Softbank | ||||
 | Colossal Biosciences | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $360.00K | -- | 1 | -- | Not available | -- | -- | $620.64M | Series C | 2/3/2026 | $380M | $10.32B | $24.89 | TWG Global, Peter Jackson, US Innovative Technology Fund, Robert Nelsen, United Arab Emirates | ||||
 | Pelage | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $150.00K | -- | 1 | -- | Not available | -- | -- | $150.75M | Series B | 10/15/2025 | $120M | $314.7M | $7.23 | ARCH Venture Partners, GV, Main Street Advisors, Visionary Ventures, YK Bioventures | ||||
 | Aspen Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $120.00K | -- | 1 | Not available | -- | -- | $339.71M | Series C | 11/20/2025 | $115.62M | $350.82M | $1.52 | OrbiMed, ARCH Venture Partners, Frazier Healthcare Partners, Revelation Partners, Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, LifeForce Capital, Kite, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures | ||||
 | Isomorphic Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $215.05K | -- | 2 | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Biosplice Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Emerald Cloud Lab | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.12M | New Series C-1 | 7/25/2025 | $65M | $335.94M | $0.51 | Undisclosed Investors | ||||
 | City Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.91M | Series B | 6/8/2026 | $99.5M | $571.5M | $14.63 | Viking Global, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures | ||||
 | Formation Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $146.34K | -- | 1 | Not available | -- | -- | $3.38B | Series D | 6/26/2024 | $372M | $1.48B | $8.18 | Andreessen Horowitz, Sanofi, Sequoia Capital, Thrive Capital, Emerson Collective, Lachy Groom, SV Angel Growth, FPV Ventures | ||||
 | Genesis Molecular AI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $340.28M | Series B-3 | 5/20/2026 | $40M | $806.79M | $9.33 | Incyte | ||||
 | Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $236.56M | Series C | 2/11/2026 | $95.46M | $614.38M | $12.26 | Age 1, Baillie Gifford | ||||
 | SURGE Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Generate Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $812.92M | Series C | 1/21/2025 | $399.4M | $2.22B | $11.85 | Amgen, Nvidia, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis | ||||
 | Mammoth Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $379.07M | Series D-3 | 12/2/2025 | $15M | $1.35B | $13.45 | Undisclosed Investors | ||||
 | ArsenalBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $2.44B | Series C | 9/4/2024 | $327.5M | $1.66B | $18.58 | ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVIDIA, Luma Group, T. Rowe Price Associates, Rock Springs Capital, Parker Institute for Cancer Immunotherapy, SoftBank, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, Hitachi Ventures | ||||
 | Capstan Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152.91M | Series C | 12/11/2024 | $110M | $355.75M | $14.43 | Eclipse, Intuitive Ventures, Yu Galaxy, Gideon Strategic Partners | ||||
 | Chai Discovery | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $103.50K | -- | 1 | -- | Not available | -- | -- | $620.17M | Series C | 7/14/2026 | $400M | $3.8B | $178.05 | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite, Scribble Ventures | ||||
 | Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | ||||